AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...
Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...
GlobalData on MSN22h
FDA approves AbbVie’s Emblaveo for intra-abdominal infectionsAbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...
Despite the death of its golden goose, AbbVie expects to achieve high single-digit compound annual sales growth to the end of ...
What's better than a good thing? More of a good thing. Income investors can find plenty of "good things" in the market these ...
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
AbbVie (ABBV) said it has received FDA approval for the combination antibiotic treatment Emblaveo, which was co-developed ...
It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.
Addresses the significant threat of antimicrobial resistance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback